|
🐜
|
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.
26 auth.
S. Gettinger,
Jungmin Choi,
K. Hastings,
A. Truini,
I. Datar,
R. Sowell,
A. Wurtz,
W. Dong,
G. Cai,
M. Melnick,
Victor Y. Du,
J. Schlessinger,
S. Goldberg,
A. Chiang,
M. Sanmamed,
...
I. Melero,
J. Agorreta,
L. Montuenga,
R. Lifton,
S. Ferrone,
P. Kavathas,
D. Rimm,
S. Kaech,
K. Schalper,
R. Herbst,
K. Politi
|
9 |
2017 |
9
🐜
|
|
🐜
|
EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.
21 auth.
N. Marcoux,
S. Gettinger,
G. O’Kane,
K. Arbour,
J. Neal,
H. Husain,
T. Evans,
J. Brahmer,
A. Muzikansky,
P. Bonomi,
...
S. D. Del Prete,
A. Wurtz,
A. Farago,
D. Dias-Santagata,
M. Mino‐Kenudson,
K. Reckamp,
H. Yu,
H. Wakelee,
F. Shepherd,
Z. Piotrowska,
L. Sequist
|
8 |
2019 |
8
🐜
|
|
🐜
|
EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer
31 auth.
K. Hastings,
H.A. Yu,
W. Wei,
F. Sánchez-Vega,
M. Deveaux,
J. Choi,
H. Rizvi,
A. Lisberg,
A. Truini,
C. Lydon,
Z. Liu,
B. Henick,
A. Wurtz,
G. Cai,
A. Plodkowski,
...
N. Long,
D. Halpenny,
J. Killam,
I. Oliva,
N. Schultz,
Gregory Riely,
M. Arcila,
M. Ladanyi,
D. Zelterman,
R. Herbst,
S. Goldberg,
M. Awad,
E. Garon,
S. Gettinger,
M. Hellmann,
K. Politi
|
8 |
2019 |
8
🐜
|
|
🐜
|
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.
20 auth.
E. D. de Bruin,
C. Cowell,
P. Warne,
M. Jiang,
R. Saunders,
M. Melnick,
S. Gettinger,
Zenta Walther,
A. Wurtz,
Guus J. J. E. Heynen,
...
D. Heideman,
J. Gómez-Román,
A. García-Castaño,
Y. Gong,
M. Ladanyi,
H. Varmus,
R. Bernards,
E. Smit,
K. Politi,
J. Downward
|
7 |
2014 |
7
🐜
|
|
🐜
|
Clinical Features and Management of Acquired Resistance to PD‐1 Axis Inhibitors in 26 Patients With Advanced Non–Small Cell Lung Cancer
12 auth.
S. Gettinger,
A. Wurtz,
S. Goldberg,
D. Rimm,
K. Schalper,
S. Kaech,
...
P. Kavathas,
A. Chiang,
R. Lilenbaum,
D. Zelterman,
K. Politi,
R. Herbst
|
6 |
2018 |
6
🐜
|
|
🐬
|
Nodule Symbiosis of Invasive Mimosa pigra in Australia and in Ancestral Habitats: A Comparative Analysis
M. Parker,
A. Wurtz,
Q. Paynter
|
6 |
2007 |
6
🐬
|
|
🐜
|
Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.
19 auth.
V. Pirazzoli,
C. Nebhan,
Xiaoling Song,
A. Wurtz,
Zenta Walther,
G. Cai,
Zhongming Zhao,
P. Jia,
E. de Stanchina,
E. Shapiro,
...
M. Gale,
Ruonan Yin,
L. Horn,
D. Carbone,
P. Stephens,
V. Miller,
S. Gettinger,
W. Pao,
K. Politi
|
6 |
2014 |
6
🐜
|
|
🐜
|
Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells.
16 auth.
M. Forloni,
Romi Gupta,
Arvindhan G. Nagarajan,
Li-Sha Sun,
Yuying Dong,
V. Pirazzoli,
Maria I Toki,
A. Wurtz,
M. Melnick,
Susumu S. Kobayashi,
...
R. Homer,
D. Rimm,
S. Gettinger,
K. Politi,
S. Dogra,
N. Wajapeyee
|
5 |
2016 |
5
🐜
|
|
🐜
|
Genetic determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo
20 auth.
Giorgia Foggetti,
Chuan Li,
Hongchen Cai,
J. Hellyer,
Wen-Yang Lin,
Deborah Ayeni,
K. Hastings,
Jungmin Choi,
A. Wurtz,
Laura Andrejka,
...
Dylan G. Maghini,
Nicholas Rashleigh,
Stellar Levy,
R. Homer,
S. Gettinger,
M. Diehn,
H. Wakelee,
D. Petrov,
M. Winslow,
K. Politi
|
5 |
2020 |
5
🐜
|
|
🐜
|
Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer.
26 auth.
Fernando J. de Miguel,
C. Gentile,
W. Feng,
Shannon J Silva,
Akshay Sankar,
F. Expósito,
Wesley L. Cai,
M. Melnick,
Camila Robles-Oteíza,
Madeline M. Hinkley,
Jeanelle Tsai,
Antja-Voy Hartley,
Jin Wei,
A. Wurtz,
Fang-yong Li,
...
Maria I Toki,
D. Rimm,
R. Homer,
Craig B. Wilen,
A. Xiao,
Jun Qi,
Q. Yan,
D. Nguyen,
P. Jänne,
Cigall Kadoch,
K. Politi
|
5 |
2023 |
5
🐜
|
